Drug Trial Radar · NCT00106691
Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)
Last checked: Nov 20, 2026Latest source record: Jun 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,589
Actual
Start
Jan 2005
Primary completion
Feb 2010
Study completion Feb 2010
Sponsor
- Lead sponsor
- GTxIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- Male only, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if toremifene citrate is effective and safe in the prevention of prostate cancer in men who have been diagnosed with high grade prostatic intraepithelial neoplasia (PIN).
Conditions
- Preneoplastic Conditions
- Prostatic Intraepithelial Neoplasia
Interventions
Toremifene 20 mgDrug
The subject takes one dose by mouth of the 20mg Toremifine Citrate tablet once a day for the length of the trial (360 days).
PlaceboDrug
The subject takes a placebo tablet identical in appearance to the toremifene 20mg tablet, administered by mouth daily for 360 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Toremifene in the Prevention of Prostate Cancer in Men With High Grade Prostatic Intraepithelial Neoplasia (PIN)Time frame: The outcome measurement time is up to 36 months
- Occurrence of a Positive Cancer BiopsyTime frame: Up to 36 months
Locations
138 sites in 3 countries. Site status is shown where the registry gives one.
Medical Affiliated Research Ctr.
Huntsville, Alabama
Coastal Clinical Research
Mobile, Alabama
Hope Research Inst.
Phoenix, Arizona
Arkansas Urology
Little Rock, Arkansas
San Bernardino Urological Associates Medical Group
San Bernardino, California
Western Clinical Research, Inc.
Torrance, California
Urology Research Options
Aurora, Colorado
Urology Associates, P.C.
Denver, Colorado
The Urology Center of Colorado
Denver, Colorado
Connecticut Surgical Group
Hartford, Connecticut
Urological Associates of Bridgeport
Trumbull, Connecticut
Connecticut Clinical Research
Waterbury, Connecticut
South Florida Medical Research
Aventura, Florida
Atlantic Urological Associates
Daytona Beach, Florida
Southwest Florida Urologic Associates
Fort Myers, Florida
Advanced Research Institute
New Port Richey, Florida
UroSearch
Ocala, Florida
Central Florida Urology Group/ UroSearch
Ocala, Florida
Florida Foundation for Healthcare Research
Ocala, Florida
Winter Park Urology Associates
Orlando, Florida
Panama City Urological Center
Panama City, Florida
Demaur Clinical Research Center
Pembroke Pines, Florida
DMI Research
Pinellas Park, Florida
Urology Consultants
Pinellas Park, Florida
Florida Urology Specialists
Sarasota, Florida
Midtown Urology
Atlanta, Georgia
Georgia Urology
Atlanta, Georgia
Urology Enterprises
Marietta, Georgia
North Fulton Urology
Roswell, Georgia
St. Joseph's, Candler Health System
Savannah, Georgia
Specialty Care Research
Peoria, Illinois
Urology of Indiana, LLC
Indianapolis, Indiana
Metropolitan Urology, PSC
Jeffersonville, Indiana
Kansas City Urology Care, P.C.
Overland Park, Kansas
Regional Urology, LLC
Shreveport, Louisiana
Anne Arundel Urology
Annapolis, Maryland
Maryland Prostate Center: University of Maryland Medical Center
Baltimore, Maryland
Drs. Werner, Murdock, & Francis PA, Urology Associates
Greenbelt, Maryland
Urology Center, PA
Hagerstown, Maryland
Mid Atlantic Clinical Research
Rockville, Maryland
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.